Literature DB >> 10419655

Abundant expression of chemokines in malignant and infective human lymphadenopathies.

N Tedla1, P Palladinetti, D Wakefield, A Lloyd.   

Abstract

Lymph nodes can be the primary target of infection or malignant transformation and may exhibit characteristic patterns of leukocyte infiltration analogous to those seen in inflammation of other tissues. Leukocyte migration to lymph nodes in vivo is a highly regulated, multi-step process that depends upon adhesion molecules and as yet, uncharacterized chemotactic signals. Chemokines are a key part of the orchestrated code of signals that directs leukocyte subsets to sites of inflammation or immune response. The potential role of these chemoattractants in selective trafficking of leukocyte subsets into lymph nodes was assessed by determining the expression of chemokines on a range of pathological and normal human lymph nodes and by evaluating the cellular composition of each lymph node. In situ hybridization using chemokine riboprobes and immunohistochemistry using specific antibodies were performed in order to correlate the mRNA and protein expression of the chemokines. The cellular source(s) of each chemokine was assessed by immunohistochemical staining of adjacent sections using antibodies directed against distinctive cellular markers. Substantial, but varied, expression of macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, RANTES, macrophage chemotactic protein (MCP)-1, eotaxin, and interleukin 8 (IL-8) were detected in the pathological lymph nodes by diverse cell types. Control lymph nodes showed expression only of RANTES, mainly by high endothelial venules. In all lymph nodes, except the nodes infiltrated with breast cancer, chemokine mRNA expression was highly concordant with the corresponding protein. In contrast with in vitro studies that have suggested discrete target cell specificity of chemokines, this study showed that with the possible exception of the neutrophil chemoattractant, IL-8, no chemokine appeared to be uniquely associated with the accumulation of a specific leukocyte subset. These data implicate chemokines in the recruitment of leukocytes to lymph nodes affected by diverse disease states. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419655     DOI: 10.1006/cyto.1998.0439

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma.

Authors:  Toni Valković; Antica Duletić-Načinović; Sanja Stifter; Milena Hasan; Ita Hadžisejdić; David Zombori; Blaženka Grahovac; Nives Jonjić
Journal:  Clin Exp Med       Date:  2010-03-16       Impact factor: 3.984

2.  CCL5 participates in early protection against Mycobacterium tuberculosis.

Authors:  Bridget Vesosky; Erin K Rottinghaus; Paul Stromberg; Joanne Turner; Gillian Beamer
Journal:  J Leukoc Biol       Date:  2010-04-06       Impact factor: 4.962

3.  The co-expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium.

Authors:  Nicodemus Tedla; Kathryn Gibson; H Patrick McNeil; David Cosman; Luis Borges; Jonathan P Arm
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

4.  Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans.

Authors:  Gali Soria; Yaeli Lebel-Haziv; Marcelo Ehrlich; Tsipi Meshel; Adva Suez; Edward Avezov; Perri Rozenberg; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

5.  Adhesive mechanisms governing interferon-producing cell recruitment into lymph nodes.

Authors:  Thomas G Diacovo; Amanda L Blasius; Tak W Mak; Marina Cella; Marco Colonna
Journal:  J Exp Med       Date:  2005-09-05       Impact factor: 14.307

Review 6.  Role of G protein-coupled receptors in control of dendritic cell migration.

Authors:  Yuan Liu; Guixiu Shi
Journal:  Biomed Res Int       Date:  2014-03-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.